Clinical Trial Detail

NCT ID NCT00740805
Title Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

non-Hodgkin lymphoma

Advanced Solid Tumor

breast cancer

triple-receptor negative breast cancer

Therapies

Aldoxorubicin + Cyclophosphamide + Veliparib

Age Groups: adult senior

Additional content available in CKB BOOST